Bemiparin sodium

贝米肝素钠

Report date: 2023/03/15 20:00:54
NME

Base Information

Drug NameBemiparin sodium
Drug Alias NameBemiparinum natricumBemiparina de sodioHiborZiborIvor +[7] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionAntithrombin-III activators
TargetsAntithrombin-III
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)FibrosisAntithrombin III Deficiency +[10] 
Global Approved IndicationsAntithrombin III Deficiency
Approved Indications in ChinaAntithrombin III Deficiency
Original Approved Country/TerritoryMainland China
Original Approved DateN/A
Country/TerritoryPolandRomaniaPortugal +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesLaboratorios Farmacéuticos Rovi Sa
Inactive CompaniesRovi Pharmaceuticals LaboratoriesHawler Medical UniversityInstituto De Investigación Marqués De Valdecilla +[5] 
Active IndicationsAntithrombin III DeficiencyVenous Thromboembolism
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)FibrosisThrombosis +[8] 

Other Information

ATC CodeB01AB12
Related LinksWikipediaDrugBankKEGG